Ectosomes, New Biomarkers of Tau Pathology? (ECTAUSOME)

University Hospital, Lille

Status: Completed

Conditions: Alzheimer Disease

Treatments: Diagnostic Test: CSF drawing during spinal anaesthesia; Diagnostic Test: Fasting blood sample; Diagnostic Test: Lumbar puncture

Study type: Observational

Funder types: Other

Identifiers

NCT03381482

2017-A01715-48 (Other Identifier)

2016_59

Details and patient eligibility

About

In Alzheimer's disease (AD), neurofibrillary degeneration (NFD) is characterized by the intraneuronal aggregation of Tau proteins. The pathology progresses through a hierarchical pathway that may be associated with the intercellular transmission of pathology as demonstrated in our rat models. This transmission implies that Tau is actively secreted and may participate to the first steps of Tau pathology spreading. It is demonstrated in cell lines and animal models (rodents and non-human primates) that Tau is secreted not only in free forms but also in extracellular vesicles. If Tau is found in biological fluids before neuronal death it may represent an early marker of the NFD and will also define therapeutically targets. In this context, the aim is now to transfer this knowledge in humans and to decipher the nature of Tau secreted in plasma and cerebrospinal fluids collected from healthy controls to AD patients, and to decipher if the presence of tau inside vesicles is influenced by the pathology.

Enrollment: 71 patients

Sex: All

Ages: 40 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subjects able to undergo a lumbar puncture;
• Subjects who have a partner who will be required for driving back the subject after the lumbar punction for safety reasons (not required for control subjects);
• Subjects (or the study partner for group 5) capable of and willing to comply with the protocol and to give their written informed consents after having received and understood the subject information. According to the legal protection or the mental capacities of the subject, he/she will be accompanied by him/her legally acceptable representative during this procedure;
• Blood coagulation testing
• Subjects registered with the French Social Security, in agreement with the French law on biomedical experimentation.

Group 1: controls

• absence of cognitive complaint
• absence of significant cognitive impairment: MMSE>27
• Negative ApoE4 status (ε 4-/ ε 4-) No family history of AD at first degree Group 2: asymptomatic cases with high risk to develop AD
• absence of cognitive complaint
• absence of significant cognitive impairment : MMSE>27
• known ApoE4 status or family history of AD at first degree Group 3: cases with isolated cognitive complaint
• presence of a cognitive complaint
• absence of cognitive impairment assessed by MMSE>27 and standard neuropsychological examination (performed < 1 year) Group 4: prodromal AD according to the 2007 criteria (Dubois et al., 2007)
• progressive and significant episodic memory impairment >6 months
• And at least one of the following: medial temporal atrophy of brain MRI / low Ab42 and increased total and phosphorylated Tau protein in the CSF/ bilateral temporoparietal hypometabolism on brain FDG-PET/ positive amyloid brain PET if available
• exclusion of any differential diagnoses Group 5: Mild to moderate probable AD-type dementia according to the NIA 2011 criteria
• progressive and significant cognitive decline >6 months
• amnestic or any other predominant clinical presentation
• exclusion of any differential diagnoses
• MMSE between 15 and 26 (inclusive)

Exclusion criteria

• Subjects with dementia caused by a non-neurodegenerative disease, including patients with severe cerebrovascular risk factor load;

Associated Illnesses or conditions:

• Subjects with other neurodegenerative disease such as fronto-temporal dementia (FTD), Lewy body dementia and Parkinson's disease;
• Subjects with other serious neurological disorder such as brain tumour, stroke, epilepsy, hydrocephalus and any condition which contraindicates, in the investigator's judgment, entry to the study;
• Subjects with demyelinating diseases of the peripheral nervous system such as Guillain-Barre Syndrome;

Biological exclusion criteria:

• Subjects with known active Hepatitis C Virus (HCV), Hepatitis B Virus (HBV) or Human Immunodeficiency Virus (HIV);
• Subjects with clinical or significant laboratory abnormalities, in the judgment of the investigator;

Others:

• Subjects with excessive alcohol intake or drug abuse, in the judgment of the investigator;
• Subjects who have contraindications to perform a lumbar puncture;
• Subjects who, in the opinion of the Investigator, have a risk of non-compliance to the study procedures or who are otherwise not appropriate to include in this clinical trial (for example, being impossible to contact in case of emergency).

Trial design

71 participants in 5 patient groups

Controls

Description:

Group 1: the 4ml of CSF collected in the surgery context will be kept for the study, and 6x5ml of blood will be added to the usual samples.

Treatment:

Diagnostic Test: Fasting blood sample

Diagnostic Test: CSF drawing during spinal anaesthesia

Asymptomatic cases with high risk to develop AD

Description:

Group 2: 10ml of CSF and 6x5ml of blood will be collected

Treatment:

Diagnostic Test: Lumbar puncture

Diagnostic Test: Fasting blood sample

Cases with isolated cognitive complaint

Description:

Group 3: 10ml of CSF and 6x5ml of blood will be collected

Treatment:

Diagnostic Test: Lumbar puncture

Diagnostic Test: Fasting blood sample

Prodromal AD

Description:

Group 4: 10ml of CSF and 6x5ml of blood will be collected

Treatment:

Diagnostic Test: Lumbar puncture

Diagnostic Test: Fasting blood sample

Mild to moderate probable AD-type dementia

Description:

Group 5: 10ml of CSF and 6x5ml of blood will be collected

Treatment:

Diagnostic Test: Lumbar puncture

Diagnostic Test: Fasting blood sample